Search the webpage

Director

Director

ABOUT

Dr. Michel Janicot holds a Ph.D. degree in Biochemistry (Molecular and Cellular Biology) from the University of Paris VII (France) after which he was Postdoctoral Fellow at The Johns Hopkins University (Baltimore, MD. USA). Dr. Janicot has over 25 years hands-on experience in preclinical and early clinical pharmaceutical drug development in increasing leadership roles at Rhone-Poulenc Rorer (Sanofi) and subsequently at Janssen (Johnson & Johnson).

Since 2012, Dr. Janicot is the founder and Managing Director of JMi ONConsulting, a firm specialized in providing consulting services and guidances for R&D programs in the field of Oncology, Inflammation, Immunology, Fibrosis and Ophthalmology. Under this business umbrella, Dr. Janicot is part-time management team member (acting CSO/CDO) in various companies. He is also co-founder and Board member of aPODD, a non-profit foundation focusing on Pediatric Oncology Drug Development.

FOLLOW

LATEST NEWS

Refinement of the EAE Mouse Model

Experimental Autoimmune Encephalomyelitis (EAE) is used to study Multiple Sclerosis (MS) a chronic neuroinflammatory demyelinating disorder of the CNS. EAE ... Read More

Novel model for corneal permeability in vitro testing through the combined use of collagen-based hydrogels with stratified corneal epithelial cells

The cornea is critical for penetration of topically applied drugs into the eye. Assessment of the permeability properties of drug ... Read More

A synthetic metalloporphyrin SOD mimetic protects corneal epithelial cells from oxidative stress-induced damage in vitro and in vivo

Keratoconjunctivitis sicca (KCS) is a multifactorial disease of the lacrimal glands and ocular surface1. Pathological findings in patients with KCS ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!